Zaks Tal Zvi sold $593 of TEVA

Zaks Tal Zvi sold 17 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.87 on 2026-08-05.

Original reporting
SEC EDGAR · Zaks Tal Zvi
Published Aug 10, 2026, 10:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (17 shares at $34.8655, $592.71 total) and post-transaction holdings (73,247 shares).

02

Market read

Traders may note the insider sale for sentiment, but the disclosed transaction size is too small to be a standalone fundamental catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing provides no rationale or follow-on buying.

Relevance 3/10Novelty 5/10Timing: filed 2026-08-10, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for TEVA, reported via SEC EDGAR.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

SEC Form 4 shows director Zaks Tal Zvi sold 17 shares of TEVA at $34.8655 on 2026-08-05, totaling $592.71.

Expected impact

Low likelihood of a sustained price move; any reaction would likely be brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size ($592.71) is small relative to a large public issuer, and there is no accompanying corporate event or guidance change in the text.

Market effects

No sector read-through is provided; this is company-specific insider selling only.

None indicated.

None indicated.

Counterpoint

Because the sale is not tied to a disclosed 10b5-1 plan, some traders may interpret it as a signal, even if the dollar amount is small.

Key entities

  • TEVA

    Teva Pharmaceutical Industries Ltd, the subject of the insider transaction filing.

  • Zaks Tal Zvi

    Director who sold 17 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.